Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study

Article Oncology

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Louisa R. Hoes et al.

Summary: This study suggests that patients with rare cancers can benefit from approved drugs similar to common cancers. Molecular testing in rare cancer patients may identify treatment opportunities and clinical benefits.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Delivering precision oncology to patients with cancer

Joaquin Mateo et al.

Summary: Precision medicine is reshaping cancer care, but accessibility to all patients remains a challenge. This Perspective highlights the importance of addressing the challenges in implementing precision oncology, including equal access to genomics tests, robust evidence for new drugs and technologies, interpretation of genomics data by physicians, and empowering patients in shared decision-making.

NATURE MEDICINE (2022)

Add to Collection

Letter Oncology

Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe

A. Lamarca et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial

Yohei Chiba et al.

Summary: This study aims to evaluate the safety and efficacy of E7090 in patients with solid tumors harboring FGFR alterations through a single-arm Phase 2 trial. The findings may serve as a novel model for the development of tumor-agnostic molecular targeted therapies against rare genetic abnormalities.

BMC CANCER (2022)

Add to Collection

Article Oncology

Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results.

Yohann Loriot et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers

A. Jahn et al.

Summary: Germline variant evaluation can identify patients with genetic tumor risk syndromes in rare cancers, guiding treatment recommendations and leading to clinical benefit. Variability in PGV yields among different precision oncology studies suggests the need for a detailed workflow for germline variant evaluation.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Letter Oncology

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A. Bayle et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

A. Haslam et al.

Summary: Previous studies have evaluated the percentage of US cancer patients who are eligible for and respond to genome-targeted therapy, with an increasing trend over time.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial

C. E. Heilig et al.

Summary: CRAFT is an open-label phase II trial targeting adults with pretreated solid tumors, aiming to evaluate efficacy through combinations of molecularly targeted agents and a PD-L1 antagonist. With a flexible design and assessment, the study is planned to be conducted at multiple centers in Germany.

ESMO OPEN (2021)

Add to Collection

Review Oncology

Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies

Mihaela Aldea et al.

Summary: Resistance to anticancer therapies can be classified into primary and secondary resistance, primarily influenced by target dependency and cellular adaptability. Immunotherapy resistance is often driven by tumor-host-microenvironment interactions, while targeted therapy resistance is typically driven by alterations in targets.

CANCER DISCOVERY (2021)

Add to Collection

Meeting Abstract Oncology